Legal Representation
Attorney
Carol H. Peters
USPTO Deadlines
Next Deadline
364 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2020-07-07)
Due Date
July 07, 2026
Grace Period Ends
January 07, 2027
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
22 events| Date | Code | Type | Description |
|---|---|---|---|
| Jul 7, 2025 | REM1 | E | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED |
| Jul 7, 2020 | R.PR | A | REGISTERED-PRINCIPAL REGISTER |
| Apr 21, 2020 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Apr 21, 2020 | PUBO | A | PUBLISHED FOR OPPOSITION |
| Apr 1, 2020 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Mar 19, 2020 | AAUA | E | NOTICE OF ACCEPTANCE OF AMENDMENT TO ALLEGE USE E-MAILED |
| Mar 18, 2020 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Mar 18, 2020 | XAEC | I | EXAMINER'S AMENDMENT ENTERED |
| Mar 18, 2020 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN |
| Mar 18, 2020 | IUAA | P | USE AMENDMENT ACCEPTED |
| Mar 18, 2020 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Mar 18, 2020 | GNEA | F | EXAMINERS AMENDMENT E-MAILED |
| Mar 17, 2020 | DOCK | D | ASSIGNED TO EXAMINER |
| Jan 23, 2020 | AUPC | I | AMENDMENT TO USE PROCESSING COMPLETE |
| Jan 23, 2020 | IUAF | S | USE AMENDMENT FILED |
| Jan 22, 2020 | EAAU | I | TEAS AMENDMENT OF USE RECEIVED |
| Jan 21, 2020 | AMPX | O | PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED |
| Jan 20, 2020 | ALIE | A | ASSIGNED TO LIE |
| Jan 7, 2020 | PARI | I | TEAS VOLUNTARY AMENDMENT RECEIVED |
| Dec 24, 2019 | MDSC | E | NOTICE OF DESIGN SEARCH CODE E-MAILED |
| Dec 21, 2019 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Dec 21, 2019 | NWAP | I | NEW APPLICATION ENTERED |
Detailed Classifications
Class 005
pharmaceutical preparations for the treatment of vascular disease, cardiovascular disease, heart disease, osteoporosis, bone disease, renal disease, kidney disease, auto immune disease, arteriosclerosis, excluding devices or drug systems for the delivery of pharmaceuticals for the treatment of allergic reactions, anaphylaxis, or asthma and pharmaceuticals for the treatment of allergic reaction, anaphylaxis or asthma
First Use Anywhere:
Jul 30, 2018
First Use in Commerce:
Jul 30, 2018
Class 042
development of pharmaceutical preparations and medicines; pharmaceutical products development; pharmaceutical research and development; research and development in the pharmaceutical and biotechnology fields; research in the field of pharmaceuticals and drugs, excluding devices or drug systems for the delivery of pharmaceuticals for the treatment of allergic reactions, anaphylaxis, or asthma and pharmaceuticals for the treatment of allergic reactions, anaphylaxis or asthma
First Use Anywhere:
Dec 23, 2019
First Use in Commerce:
Dec 23, 2019
Additional Information
Design Mark
The mark consists of the word "EPIZON" featuring a benzene ring as the "O" followed by the word "PHARMA".
Color Claim
Color is not claimed as a feature of the mark.
Classification
International Classes
005
042
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"PHARMA"